Tags

Type your tag names separated by a space and hit enter

Management of Polycythemia Vera: A Survey of Canadian Physician Practice Patterns.
Clin Lymphoma Myeloma Leuk 2019; 19(1):e37-e42CL

Abstract

BACKGROUND

The 2016 World Health Organization (WHO) revised classification criteria for the diagnosis of polycythemia vera (PV) allows for an earlier detection of masked PV. The literature is scarce about the clinical uptake of new diagnostic algorithms for PV. In a cohort of Canadian hematologists, we aimed to identify how the revised 2016 WHO diagnostic criteria of PV are being incorporated into hematology practice, and if the treatment of PV is comparable to the approaches outlined by the Canadian Myeloproliferative Neoplasm Group.

MATERIALS AND METHODS

A cross-sectional survey of practicing Canadian hematologists/oncologists was distributed to active members of the Canadian Hematology Society using an online survey-distributing website. Univariate and multivariate analysis was performed.

RESULTS

The survey was completed by 86 respondents in total. Only type of practice was associated with respondents offering aspirin to all patients with PV (P = .0009). Respondents who were aware of the Canadian Myeloproliferative Neoplasm Group guidelines were more likely to phlebotomize patients to a target hematocrit of < 45% irrespective of gender (P = .042). Younger practitioners were more likely to use age over 60 years as an indication for initiating cytoreductive therapy (P = .0006). Most (85.3%) respondents would recommend indefinite anticoagulation in patients with PV who developed unprovoked venous thromboembolism.

CONCLUSION

The survey confirmed that heterogeneity of practice in diagnosis and management of PV among Canadian hematologists exists, suggesting that targeted education in specific segments of the PV treatment providers may result in wider adoption of the guidelines and diagnostic criteria.

Authors+Show Affiliations

Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada. Electronic address: laura.habib@mail.mcgill.ca.Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada.Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada.Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada.Division of Hematology/Oncology, St. Michael's Hospital, University of Toronto, Toronto, Canada.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30322792

Citation

Habib, Laura Anne, et al. "Management of Polycythemia Vera: a Survey of Canadian Physician Practice Patterns." Clinical Lymphoma, Myeloma & Leukemia, vol. 19, no. 1, 2019, pp. e37-e42.
Habib LA, Kuo KHM, Panzarella T, et al. Management of Polycythemia Vera: A Survey of Canadian Physician Practice Patterns. Clin Lymphoma Myeloma Leuk. 2019;19(1):e37-e42.
Habib, L. A., Kuo, K. H. M., Panzarella, T., Gupta, V., & Trinkaus, M. (2019). Management of Polycythemia Vera: A Survey of Canadian Physician Practice Patterns. Clinical Lymphoma, Myeloma & Leukemia, 19(1), pp. e37-e42. doi:10.1016/j.clml.2018.07.297.
Habib LA, et al. Management of Polycythemia Vera: a Survey of Canadian Physician Practice Patterns. Clin Lymphoma Myeloma Leuk. 2019;19(1):e37-e42. PubMed PMID: 30322792.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Management of Polycythemia Vera: A Survey of Canadian Physician Practice Patterns. AU - Habib,Laura Anne, AU - Kuo,Kevin H M, AU - Panzarella,Tony, AU - Gupta,Vikas, AU - Trinkaus,Martina, Y1 - 2018/08/31/ PY - 2018/04/09/received PY - 2018/07/21/revised PY - 2018/07/27/accepted PY - 2018/10/17/pubmed PY - 2018/10/17/medline PY - 2018/10/17/entrez KW - Diagnostic criteria KW - Guidelines KW - MPN KW - Management KW - Polycythemia vera SP - e37 EP - e42 JF - Clinical lymphoma, myeloma & leukemia JO - Clin Lymphoma Myeloma Leuk VL - 19 IS - 1 N2 - BACKGROUND: The 2016 World Health Organization (WHO) revised classification criteria for the diagnosis of polycythemia vera (PV) allows for an earlier detection of masked PV. The literature is scarce about the clinical uptake of new diagnostic algorithms for PV. In a cohort of Canadian hematologists, we aimed to identify how the revised 2016 WHO diagnostic criteria of PV are being incorporated into hematology practice, and if the treatment of PV is comparable to the approaches outlined by the Canadian Myeloproliferative Neoplasm Group. MATERIALS AND METHODS: A cross-sectional survey of practicing Canadian hematologists/oncologists was distributed to active members of the Canadian Hematology Society using an online survey-distributing website. Univariate and multivariate analysis was performed. RESULTS: The survey was completed by 86 respondents in total. Only type of practice was associated with respondents offering aspirin to all patients with PV (P = .0009). Respondents who were aware of the Canadian Myeloproliferative Neoplasm Group guidelines were more likely to phlebotomize patients to a target hematocrit of < 45% irrespective of gender (P = .042). Younger practitioners were more likely to use age over 60 years as an indication for initiating cytoreductive therapy (P = .0006). Most (85.3%) respondents would recommend indefinite anticoagulation in patients with PV who developed unprovoked venous thromboembolism. CONCLUSION: The survey confirmed that heterogeneity of practice in diagnosis and management of PV among Canadian hematologists exists, suggesting that targeted education in specific segments of the PV treatment providers may result in wider adoption of the guidelines and diagnostic criteria. SN - 2152-2669 UR - https://www.unboundmedicine.com/medline/citation/30322792/Management_of_Polycythemia_Vera:_A_Survey_of_Canadian_Physician_Practice_Patterns L2 - https://linkinghub.elsevier.com/retrieve/pii/S2152-2650(18)30239-8 DB - PRIME DP - Unbound Medicine ER -